Human mesenchymal stem cell therapy in the management of luminal and perianal fistulizing Crohn’s disease–review of pathomechanism and existing clinical data

Renáta Bor, Anna Fábián, Klaudia Farkas, T. Molnár, Zoltán Szepes

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Crohn’s disease (CD) is a chronic, recurring, idiopathic disease which is associated with imbalanced mucosal immune response, manifesting as a chronic inflammation of any location throughout the gastrointestinal tract. The purpose of currently available therapy is to suppress the heightened immune response. However, these treatments have no direct influence on the healing process of damaged tissues. The mesenchymal stem cell (MSC) therapy may represent a new alternative solution in both luminal and fistulizing CD, as it is able to inhibit the inflammation and promote the regeneration process at the same time. Areas covered: Aim of this review is to summarize the existing clinical data about the clinical impact of MSC therapy in luminal and perianal fistulizing CD. Expert opinion: Clinical trials demonstrated that MSC transplantation has an outstanding, durable efficacy with low fistula recurrence in biological therapy-refractory fistulizing CD; however, further clinical trials are required to confirm its effectiveness in luminal CD. Unlike to biological therapy, MSCs are able to promote the regeneration process of damaged tissues as well. This additional benefit besides their sustained immunosuppressive effect with no decrease of efficiency over time makes MSCs a new, highly potential therapeutic approach in the management of inflammatory bowel disease.

Original languageEnglish
Pages (from-to)737-745
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume18
Issue number7
DOIs
Publication statusPublished - Jul 3 2018

Fingerprint

Cell- and Tissue-Based Therapy
Stem cells
Mesenchymal Stromal Cells
Crohn Disease
Biological Therapy
Regeneration
Clinical Trials
Mesenchymal Stem Cell Transplantation
Inflammation
Mucosal Immunity
Expert Testimony
Immunosuppressive Agents
Tissue
Inflammatory Bowel Diseases
Fistula
Gastrointestinal Tract
Therapeutics
Refractory materials
Recurrence

Keywords

  • Crohn’s disease
  • fistula
  • inflammatory bowel disease
  • mesenchymal stem cell

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Human mesenchymal stem cell therapy in the management of luminal and perianal fistulizing Crohn’s disease–review of pathomechanism and existing clinical data. / Bor, Renáta; Fábián, Anna; Farkas, Klaudia; Molnár, T.; Szepes, Zoltán.

In: Expert Opinion on Biological Therapy, Vol. 18, No. 7, 03.07.2018, p. 737-745.

Research output: Contribution to journalReview article

@article{95ba9fdf01fc442c9d89eec04460e2b0,
title = "Human mesenchymal stem cell therapy in the management of luminal and perianal fistulizing Crohn’s disease–review of pathomechanism and existing clinical data",
abstract = "Introduction: Crohn’s disease (CD) is a chronic, recurring, idiopathic disease which is associated with imbalanced mucosal immune response, manifesting as a chronic inflammation of any location throughout the gastrointestinal tract. The purpose of currently available therapy is to suppress the heightened immune response. However, these treatments have no direct influence on the healing process of damaged tissues. The mesenchymal stem cell (MSC) therapy may represent a new alternative solution in both luminal and fistulizing CD, as it is able to inhibit the inflammation and promote the regeneration process at the same time. Areas covered: Aim of this review is to summarize the existing clinical data about the clinical impact of MSC therapy in luminal and perianal fistulizing CD. Expert opinion: Clinical trials demonstrated that MSC transplantation has an outstanding, durable efficacy with low fistula recurrence in biological therapy-refractory fistulizing CD; however, further clinical trials are required to confirm its effectiveness in luminal CD. Unlike to biological therapy, MSCs are able to promote the regeneration process of damaged tissues as well. This additional benefit besides their sustained immunosuppressive effect with no decrease of efficiency over time makes MSCs a new, highly potential therapeutic approach in the management of inflammatory bowel disease.",
keywords = "Crohn’s disease, fistula, inflammatory bowel disease, mesenchymal stem cell",
author = "Ren{\'a}ta Bor and Anna F{\'a}bi{\'a}n and Klaudia Farkas and T. Moln{\'a}r and Zolt{\'a}n Szepes",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/14712598.2018.1492543",
language = "English",
volume = "18",
pages = "737--745",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Human mesenchymal stem cell therapy in the management of luminal and perianal fistulizing Crohn’s disease–review of pathomechanism and existing clinical data

AU - Bor, Renáta

AU - Fábián, Anna

AU - Farkas, Klaudia

AU - Molnár, T.

AU - Szepes, Zoltán

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Introduction: Crohn’s disease (CD) is a chronic, recurring, idiopathic disease which is associated with imbalanced mucosal immune response, manifesting as a chronic inflammation of any location throughout the gastrointestinal tract. The purpose of currently available therapy is to suppress the heightened immune response. However, these treatments have no direct influence on the healing process of damaged tissues. The mesenchymal stem cell (MSC) therapy may represent a new alternative solution in both luminal and fistulizing CD, as it is able to inhibit the inflammation and promote the regeneration process at the same time. Areas covered: Aim of this review is to summarize the existing clinical data about the clinical impact of MSC therapy in luminal and perianal fistulizing CD. Expert opinion: Clinical trials demonstrated that MSC transplantation has an outstanding, durable efficacy with low fistula recurrence in biological therapy-refractory fistulizing CD; however, further clinical trials are required to confirm its effectiveness in luminal CD. Unlike to biological therapy, MSCs are able to promote the regeneration process of damaged tissues as well. This additional benefit besides their sustained immunosuppressive effect with no decrease of efficiency over time makes MSCs a new, highly potential therapeutic approach in the management of inflammatory bowel disease.

AB - Introduction: Crohn’s disease (CD) is a chronic, recurring, idiopathic disease which is associated with imbalanced mucosal immune response, manifesting as a chronic inflammation of any location throughout the gastrointestinal tract. The purpose of currently available therapy is to suppress the heightened immune response. However, these treatments have no direct influence on the healing process of damaged tissues. The mesenchymal stem cell (MSC) therapy may represent a new alternative solution in both luminal and fistulizing CD, as it is able to inhibit the inflammation and promote the regeneration process at the same time. Areas covered: Aim of this review is to summarize the existing clinical data about the clinical impact of MSC therapy in luminal and perianal fistulizing CD. Expert opinion: Clinical trials demonstrated that MSC transplantation has an outstanding, durable efficacy with low fistula recurrence in biological therapy-refractory fistulizing CD; however, further clinical trials are required to confirm its effectiveness in luminal CD. Unlike to biological therapy, MSCs are able to promote the regeneration process of damaged tissues as well. This additional benefit besides their sustained immunosuppressive effect with no decrease of efficiency over time makes MSCs a new, highly potential therapeutic approach in the management of inflammatory bowel disease.

KW - Crohn’s disease

KW - fistula

KW - inflammatory bowel disease

KW - mesenchymal stem cell

UR - http://www.scopus.com/inward/record.url?scp=85049873323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049873323&partnerID=8YFLogxK

U2 - 10.1080/14712598.2018.1492543

DO - 10.1080/14712598.2018.1492543

M3 - Review article

VL - 18

SP - 737

EP - 745

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 7

ER -